IKT IPOs 2.07M* shares @$10.00: https://www.prnewswire.com/news-releases/inhibikase-therapeutics-inc-announces-pricing-of-its-initial-public-offering-301197852.html Inhibikase is a clinical-stage pharmaceutical company developing therapeutics for Parkinson's Disease and related disorders that arise inside and outside of the brain. *Assuming exercise of underwriter’s option.